Clinical Trials for Urothelial Carcinoma
252 urothelial carcinoma trials indexed, 119 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Urothelial Carcinoma
Urothelial carcinoma is a type of cancer that originates in the urothelial cells lining the inside of the urinary tract. These cells are found in the bladder, ureters, and parts of the kidneys. The cancer develops when these cells grow uncontrollably, forming tumors. Diagnosis often involves a combination of urine tests, cystoscopy (a procedure using a camera to look inside the bladder), and imaging scans like CT or MRI. A biopsy, where a small tissue sample is taken for microscopic examination, confirms the presence of cancer cells and helps determine the tumor grade and stage.
This cancer most commonly affects the bladder but can also appear in the upper urinary tract. Symptoms typically include blood in the urine (hematuria), frequent urination, pain during urination, and lower back pain. Urothelial carcinoma usually occurs in people over 65 years old, with men being more frequently diagnosed than women. Risk factors include smoking, exposure to certain industrial chemicals, chronic bladder inflammation, and a history of bladder infections or stones. The disease is more common in developed countries, partly due to environmental and lifestyle factors.
Urothelial carcinoma is a significant health concern because it is the sixth most common cancer in the United States. According to recent data, about 81,000 new cases are diagnosed annually in the U.S. alone. The disease also carries a high risk of recurrence and progression, which makes long-term management challenging. Economically, it imposes a substantial burden on healthcare systems due to frequent monitoring and treatments. Early diagnosis and effective treatment are critical to improving patient outcomes and reducing the social impact of this disease.
The Urothelial Carcinoma Treatment Landscape
The first-line treatment for urothelial carcinoma depends on the stage and grade of the tumor. For non-muscle invasive bladder cancer, the standard care often includes transurethral resection of the bladder tumor (TURBT) followed by intravesical therapy, such as Bacillus Calmette-Guérin (BCG) immunotherapy. Muscle-invasive bladder cancer typically requires more aggressive treatment, including radical cystectomy (bladder removal) combined with chemotherapy. Platinum-based chemotherapy, such as cisplatin, is commonly used before or after surgery to improve survival chances. Treatment plans are usually tiered based on the tumor's extent and the patient's overall health.
For patients whose cancer progresses or does not respond to first-line therapies, second- and third-line options include immune checkpoint inhibitors and targeted therapies. Immune checkpoint inhibitors like atezolizumab and pembrolizumab belong to the class of drugs called PD-1 or PD-L1 inhibitors. These drugs help the immune system recognize and attack cancer cells. Other options may include chemotherapy agents like taxanes or vinflunine, depending on prior treatments and patient tolerance. The choice of therapy beyond first-line depends on various factors including tumor biology and patient preferences.
Despite available treatments, many challenges remain. Some patients do not respond well to chemotherapy or immunotherapy, and resistance can develop over time. Side effects from treatments can be severe, affecting quality of life and limiting options. Certain subgroups, such as older adults or those with kidney impairment, may not tolerate standard therapies well. Research is focused on finding new drugs that work better and have fewer side effects, as well as on identifying biomarkers to predict which patients will benefit most from specific treatments. Closing these gaps is essential for improving outcomes in urothelial carcinoma.
Why Clinical Trials Matter for Urothelial Carcinoma
Clinical trials offer patients with urothelial carcinoma access to new treatments that are not yet widely available. These studies help evaluate the safety and effectiveness of experimental therapies, potentially providing options when standard treatments fail. Patients in trials often receive closer monitoring and comprehensive care. According to ClinicalTrials.gov, there are currently 252 urothelial carcinoma clinical trials indexed, with 119 actively recruiting participants. This large number reflects ongoing efforts to improve treatment and understand the disease better.
Participating in a clinical trial also involves certain risks. The effectiveness of new treatments is not guaranteed, and some patients may receive a placebo or standard treatment instead of the experimental drug. Additional clinic visits and tests may be required, which can be time-consuming. Side effects from investigational treatments may occur and sometimes be more severe than those from approved therapies. It is important for patients and caregivers to weigh these factors carefully and discuss them with their healthcare team before enrolling.
Clinical trials for urothelial carcinoma are sponsored by a variety of organizations. Academic institutions conduct many investigator-initiated studies, while pharmaceutical companies often lead trials for new drugs. Cooperative groups, which are networks of research centers, also play a key role in running large trials. ClinicalTrials.gov serves as a central registry where patients and doctors can find detailed information about ongoing studies. This transparency helps connect patients with trials that might fit their needs and supports the development of better treatments for urothelial carcinoma.
What to Look for in a Urothelial Carcinoma Clinical Trial
Clinical trials for urothelial carcinoma are organized into phases that help researchers test new treatments safely and effectively. Phase 1 trials focus on safety and dosage, usually involving a small number of participants. Phase 2 trials test how well the treatment works and continue to evaluate safety. Phase 3 trials compare the new treatment to the current standard, often with many participants. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For urothelial carcinoma, there are currently 81 Phase 1 trials, 63 Phase 2, 38 Phase 3, and 23 trials with no phase specified.
When joining a urothelial carcinoma trial, participants must meet specific inclusion criteria. These often include age limits, such as adults 18 years or older. Patients may need to have a confirmed diagnosis of urothelial carcinoma at a certain stage. Trials might require previous treatments, like chemotherapy or surgery, to have been completed or not yet started. Some studies look for specific biomarkers or genetic markers to see if the treatment targets those changes. The duration of the disease and overall health status can also affect eligibility.
Exclusion criteria help protect patients and ensure clear results. People with serious other health problems, like heart or liver disease, might be excluded to avoid complications. Those taking medications that could interfere with the trial drug may not qualify. Safety thresholds, such as certain blood test results, help determine if a patient is healthy enough for the trial. These rules help keep patients safe and make sure the study measures the treatment’s effects accurately.
Participating in a clinical trial requires practical planning. Trials can last from a few weeks to several months or longer. Patients often need to visit the clinic regularly for treatments, tests, and check-ups. Travel to the trial site may be necessary, which can affect time and costs. It is important to ask the research team key questions: What are the possible side effects? How often will I need to come for visits? What happens if I want to stop the trial? Are there costs I should expect to pay? Knowing these details helps patients and caregivers make informed choices.
Primary Sources and Further Reading
For those interested in learning more about urothelial carcinoma and clinical trials, several trusted sources offer detailed and up-to-date information. These sites provide guidance on the disease, treatment options, and how to find and participate in clinical trials. They are useful for patients, caregivers, and anyone seeking reliable medical knowledge.
- National Cancer Institute: Bladder Cancer Treatment
- MedlinePlus: Bladder Cancer
- ClinicalTrials.gov: Urothelial Carcinoma Trials
- Centers for Disease Control and Prevention: Bladder Cancer
Latest Research and Emerging Treatments for Urothelial Carcinoma (2026)
Current urothelial carcinoma research includes several Phase 3 trials testing new drugs and treatment strategies. One important area is immune checkpoint inhibitor therapy. Drugs like pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab help the immune system recognize and attack cancer cells. A trial led by the Alliance for Clinical Trials in Oncology (NCT04637594) is exploring whether stopping this immune therapy after about a year is as effective as continuing it longer. This could reduce side effects and lower treatment costs for patients with advanced urothelial carcinoma.
Another study focuses on combining immunotherapy with chemotherapy before surgery for muscle-invasive bladder cancer. AstraZeneca is sponsoring a trial (NCT03732677) that uses durvalumab together with gemcitabine and cisplatin before surgery, followed by durvalumab alone after surgery. This approach aims to improve survival rates by attacking the cancer from multiple angles. For patients, this could mean better control of aggressive tumors and possibly longer disease-free periods.
New drugs targeting specific cancer markers are also under study. Erdafitinib, a drug that targets FGFR gene changes in urothelial carcinoma cells, is being tested against chemotherapy and pembrolizumab (NCT03390504). This targeted approach may offer new options for patients who have already tried other treatments. Additionally, a trial comparing disitamab vedotin combined with pembrolizumab versus standard chemotherapy is underway for patients with HER2-expressing urothelial cancer (NCT05911295). Disitamab vedotin is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells, potentially improving effectiveness and reducing side effects. These new drugs for urothelial carcinoma could provide more personalized treatment choices in 2026 and beyond.
Frequently asked questions about Urothelial Carcinoma trials
How do I find Urothelial Carcinoma clinical trials?
The authoritative source for Urothelial Carcinoma clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 252 urothelial carcinoma studies are currently indexed. You can search by entering "urothelial carcinoma" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new urothelial carcinoma trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Urothelial Carcinoma trials in?
Across the 252 urothelial carcinoma trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Urothelial Carcinoma clinical trials are currently recruiting?
As of the latest scan, 119 urothelial carcinoma trials have a "Recruiting" status on ClinicalTrials.gov, out of 252 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting urothelial carcinoma trial matches their tracked condition.
Stay informed about urothelial carcinoma research
Get a weekly briefing with the trials that matter most.